Biofrontera Inc. Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost
Biofrontera Inc. (BFRI) had Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost of $96.00 thousand as of 2022-12-31, per its 10-K filed 2024-03-15.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost · last filed 2024-03-15
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $96.00K.
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $187.00K.
- 2020-12-31: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $279.00K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost |
|---|---|
| 2022-12-31 | $96.00K 10-K · filed 2024-03-15 |
| 2021-12-31 | $187.00K 8-K · filed 2023-10-03 |
| 2020-12-31 | $279.00K 10-K · filed 2022-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |